The question of whether beneficial effects may be noted after combination of CCR5 inhibitors with antiretroviral regimens for MS treatment warrants further research, as so far, no in vitro or animal model studies exist regarding efficacy of combined chemokine receptor inhibitors and antiretroviral drugs in MS. The gene discussed is CCR5; the disease is myeloid sarcoma.